Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla, Haley Hedlin, Karen B. Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R. de Vries, Orlando Quintero, Kent Feng, Catherine Ley, Dean Winslow, Jennifer Newberry, Karlie Edwards, Colin Hislop, Ingrid Choong, Yvonne Maldonado, Jeffrey Glenn, Ami Bhatt, Catherine Blish, Taia Wang, Chaitan Khosla, Benjamin A. Pinsky, Manisha Desai, Julie Parsonnet, Upinder Singh
doi: https://doi.org/10.1101/2020.11.18.20234161
Prasanna Jagannathan
1Department of Medicine, Stanford University, Stanford, CA, USA
2Department of Microbiology and Immunology, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: prasj@stanford.edu usingh@stanford.edu
Jason R. Andrews
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hector Bonilla
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haley Hedlin
3Quantitative Sciences Unit, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen B. Jacobson
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vidhya Balasubramanian
3Quantitative Sciences Unit, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha Purington
3Quantitative Sciences Unit, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savita Kamble
4Stanford Center for Clinical Research, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiaan R. de Vries
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orlando Quintero
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kent Feng
4Stanford Center for Clinical Research, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Ley
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean Winslow
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Newberry
5Department of Emergency Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karlie Edwards
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Hislop
6Department of Pediatrics, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Choong
6Department of Pediatrics, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvonne Maldonado
7Eiger BioPharmaceuticals, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Glenn
1Department of Medicine, Stanford University, Stanford, CA, USA
2Department of Microbiology and Immunology, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ami Bhatt
1Department of Medicine, Stanford University, Stanford, CA, USA
8Department of Genetics, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Blish
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taia Wang
1Department of Medicine, Stanford University, Stanford, CA, USA
2Department of Microbiology and Immunology, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaitan Khosla
9ChEM-H, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin A. Pinsky
1Department of Medicine, Stanford University, Stanford, CA, USA
10Department of Pathology, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manisha Desai
3Quantitative Sciences Unit, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Parsonnet
1Department of Medicine, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Upinder Singh
1Department of Medicine, Stanford University, Stanford, CA, USA
2Department of Microbiology and Immunology, Stanford University, Stanford, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized placebo-controlled trial in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint, NCT04331899). In both the 60 patients receiving Lambda and the 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively (HR 0.94; 95% CI 0.64 to 1.39). At enrollment; 41% of subjects were SARS-CoV-2 IgG seropositive; compared to placebo, lambda tended to delay shedding cessation in seronegatives (aHR 0.66, 95% CI 0.39-1.10) and to hasten shedding cessation in seropositives (aHR 1.58, 95% CI 0.88-2.86; p for interaction = 0.03). Liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.

Competing Interest Statement

Colin Hislop and Ingrid Choong are scientists at Eiger BioPharmaceuticals, Inc., which provided the Interferon Lambda used for this study. Jeffrey Glenn serves on the board of Eiger BioPharmaceuticals, Inc. Colin Hislop and Ingrid Choong own stock and options of Eiger BioPharmaceuticals, Inc. Jeffrey Glenn has an equity interest in Eiger BioPharmaceuticals, Inc. Jeffrey Glenn and Ingrid Choong are inventors on a pending patent application relating to the use of interferon lambda for coronavirus. Eiger BioPharmaceuticals played no role in study design, conduct of the study, or analysis of the data.

Clinical Trial

ClinicalTrials.gov NCT04331899

Funding Statement

The study was funded by anonymous donors to Stanford University, and Lambda provided by Eiger BioPharmaceuticals. The funders had no role in data collection and analysis or the decision to publish.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Stanford University Institutional Review Board

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be made available at Stanford Digital Repository, lane.stanford.edu, at time of final publication.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 23, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla, Haley Hedlin, Karen B. Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R. de Vries, Orlando Quintero, Kent Feng, Catherine Ley, Dean Winslow, Jennifer Newberry, Karlie Edwards, Colin Hislop, Ingrid Choong, Yvonne Maldonado, Jeffrey Glenn, Ami Bhatt, Catherine Blish, Taia Wang, Chaitan Khosla, Benjamin A. Pinsky, Manisha Desai, Julie Parsonnet, Upinder Singh
medRxiv 2020.11.18.20234161; doi: https://doi.org/10.1101/2020.11.18.20234161
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla, Haley Hedlin, Karen B. Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R. de Vries, Orlando Quintero, Kent Feng, Catherine Ley, Dean Winslow, Jennifer Newberry, Karlie Edwards, Colin Hislop, Ingrid Choong, Yvonne Maldonado, Jeffrey Glenn, Ami Bhatt, Catherine Blish, Taia Wang, Chaitan Khosla, Benjamin A. Pinsky, Manisha Desai, Julie Parsonnet, Upinder Singh
medRxiv 2020.11.18.20234161; doi: https://doi.org/10.1101/2020.11.18.20234161

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (74)
  • Dermatology (49)
  • Emergency Medicine (148)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (176)
  • Epidemiology (4908)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (690)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (325)
  • Health Systems and Quality Improvement (209)
  • Hematology (87)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5414)
  • Intensive Care and Critical Care Medicine (334)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (130)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (203)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (788)
  • Public and Global Health (1833)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (258)
  • Rheumatology (88)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (39)